

Date: 29th May 2023

To The Manager Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001

Dear Sir/Madam,

<u>BSE Scrip: PHARMAID | Code: 524572 ISIN: INE117D01018|</u> Sub: Statement of NIL deviation(s) or variation(s) under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, for the quarter ended March 31, 2023

Pursuant to the provisions of Regulation 32 of the Securities and Exchange Board of India ["SEBI"] (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th December 2019, we hereby confirm that there is no deviation or variation in the use of proceeds of Preferential Issue of share Warrants. A "Nil" Statement of Deviation, duly reviewed by the Audit Committee of the Company, is given in "Annexure A".

The proceeds raised by the Company through Preferential Issue have been utilised for the original objects as stated. We request you to kindly take the enclosed annexure on records.

Thanking you Yours faithfully

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)



ANNEXURE A

NIL Statement of Deviation / Variation in utilisation of funds raised

Name of	Pharmaids Pharmaceuticals Limited					
listed entity						
Mode of	Allotment of 37,00,000	Allotment of Equity	Allotment of 84,00,000 equity			
Fund Raising	convertible share warrants	Shares, consequent to the	shares at the face value of Rs.			
	having a face value of Rs.	conversion of 27,75,000	10/- each at a premium of Rs.			
	10/- (Ten) each at a premium	Share warrants issued on	10/- each on preferential issue			
	of Rs. 5/- (Five) each on	preferential basis (out of	basis as per the terms of issue			
	preferential basis on 13 th	37,00,000 convertible				
	October 2022	share warrants allotted on				
		13 th October 2022)]				
Date of	13 th October 2022	6 th December 2022	17 th January 2023			
Raising						
Funds						
Amount	*Rs. 1,38,75,000/- (Rupees	** Rs. 3,12,18,750/-	*** 16,80,00,000/-			
Raised	One Crore Thirty-Eight Lakh	(Rupees Three Crore	(Rupees Sixteen Crores			
	Seventy-Five Thousand	Twelve Lakh Eighteen	Eighty Lakh Only)			
	Only)	Thousand Seven Hundred				
		Fifty Only)				
Report filed	31 st March 2023	31 st March 2023	31 st March 2023			
for Quarter						
ended						
Monitoring	Not Applicable	Not Applicable	Not Applicable			
Agency						
Monitoring	Not Applicable	Not Applicable	Not Applicable			
Agency						
Name, if						
applicable						
Is there a	No	No	No			
Deviation /						
Variation in						
use of funds						
raised						
If yes,	Not Applicable	Not Applicable	Not Applicable			
whether the						
same is						
pursuant to						
change in						



Antical Science Pharmaceuticals Limited

terms of a contract or objects, which was approved by							
the shareholders							
If Yes, Date of shareholder Approval	Not Applic	cable	Not App	olicable	Not Applicable		
Explanation for the Deviation / Variation	Not Applic	cable	Not App	olicable	Not Applicable		
Comments of the Audit Committee after review	Nil		Nil		Nil	Nil	
Comments of the auditors, if any	Nil		Nil		Nil		
-	1		1		deviation, in the follow	_	
Original	Modified	Original	Modified	Funds	Amount of	Remarks	
Object	Object,	Allocation	allocation,	Utilised	Deviation/Variation	if any	
	if any		if any		for the quarter according to		
Allotment of	NA	1,38,75,000/-	NA	1,38,75,000/-	applicable object		



🧈 Pharmaids Pharmaceuticals Limited

October						
2022						
To meet						
Working						
Capital						
Requirements						
and part-						
finance the						
business						
expansion						
programme						
Allotment of	NA	3,12,18,750/-	NA	3,12,18,750/-	NA	
Equity	1.1.1	0,12,10,700		0,12,10,700		
Shares,						
consequent						
to the						
conversion						
of 27,75,000						
Share						
warrants						
issued on						
preferential						
basis						
To meet						
Working						
Capital						
Requirements						
and part-						
finance the						
business						
expansion						
programme						
Allotment of	NA	16,80,00,000/-	NA	4,07,16,242/-	NA	
84,00,000				, , ,		
equity						
shares at the						
face value of						
Rs. 10/- each						
at a						
premium of						
Rs. 10/- each						
on						



Pharmaids Pharmaceuticals Limited

preferential				
issue basis				
General				
Business				
Purpose,				
Business				
Expansion &				
Working				
Capital				
Requirement				
Deviation and variation	n could mean:		I	
(a) Deviation in the obj	iects or purposes for which	the funds have been rais	sed or	
(b) Deviation in the am	ount of funds actually util	lized as against what was	originally disclosed or	
(c) Change in terms of	a contract referred to in th	he fund raising document	i.e. prospectus, letter o	of offer,
etc				

*As per regulation 169 (2) of the SEBI (Issue of Capital & Disclosure Requirements) Regulation, 2018, "*in case of warrants an amount equivalent to 25% of consideration amount to be paid on the date allotment and balance 75% of the consideration shall be paid within eighteen months from the date of allotment.*" Accordingly, the Company received Rs. 1,38,75,000/- (Rupees One Crore Thirty-Eight Lakh Seventy-Five Thousand Only) which is 25% of the total consideration i.e., Rs. 5,55,00,000/- (Rupees Five Crore Fifty-Five Lakh Only).

** Company had allotted 37,00,000 Convertible Share Warrants on 13th October 2022. Out of said 37,00,000 Convertible Share Warrants, the Company has received the remaining 75% amount for 27,75,000 Convertible Share Warrants amounting to Rs. 3,12,18,750/- (Rupees Three Crore Twelve Lakh Eighteen Thousand Seven Hundred Fifty Only).

*** Company had allotted 84,00,000 equity shares having a face value of Rs. 10/- each at a premium of Rs. 10/- each aggregating to Rs.16,80,00,000/- (Rupees Sixteen Crore Eighty Lakh Only) on preferential issue basis on 17th January 2023.

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)